Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries

Dana Ferraris, Rica Pargas Ficco, David Dain, Mark Ginski, Susan Lautar, Kathy Lee-Wisdom, Shi Liang, Qian Lin, May X C Lu, Lisa Morgan, Bert Thomas, Lawrence R. Williams, Jie Zhang, Yinong Zhou, Vincent J. Kalish

Research output: Contribution to journalArticle

Abstract

A class of poly(ADP-ribose) polymerase (PARP-1) inhibitors, the imidazobenzodiazepines, are presented in this text. Several derivatives were designed and synthesized with ionizable groups (i.e., tertiary amines) in order to promote the desired pharmaceutical characteristics for administration in ischemic injury. Within this series, several compounds have excellent in vitro potency and our computational models accurately justify the structure-activity relationships (SARs) and highlight essential hydrogen bonding residues and hydrophobic pockets within the catalytic domain of PARP-1. Administration of these compounds (5q, 17a and 17e) in the mouse model of streptozotocin-induced diabetes results in maintainance of glucose levels. Furthermore, one such inhibitor (5g, IC50=26 nM) demonstrated significant reduction of infarct volume in the rat model of permanent focal cerebral ischemia.

Original languageEnglish (US)
Pages (from-to)3695-3707
Number of pages13
JournalBioorganic and Medicinal Chemistry
Volume11
Issue number17
DOIs
StatePublished - Aug 15 2003
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Experimental Diabetes Mellitus
Wounds and Injuries
Hydrogen Bonding
Structure-Activity Relationship
Brain Ischemia
Inhibitory Concentration 50
Amines
Catalytic Domain
Streptozocin
Medical problems
Glucose
Rats
Hydrogen bonds
Pharmaceutical Preparations
Derivatives
Poly (ADP-Ribose) Polymerase-1
Poly(ADP-ribose) Polymerase Inhibitors
In Vitro Techniques

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4 : Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. / Ferraris, Dana; Ficco, Rica Pargas; Dain, David; Ginski, Mark; Lautar, Susan; Lee-Wisdom, Kathy; Liang, Shi; Lin, Qian; Lu, May X C; Morgan, Lisa; Thomas, Bert; Williams, Lawrence R.; Zhang, Jie; Zhou, Yinong; Kalish, Vincent J.

In: Bioorganic and Medicinal Chemistry, Vol. 11, No. 17, 15.08.2003, p. 3695-3707.

Research output: Contribution to journalArticle

Ferraris, D, Ficco, RP, Dain, D, Ginski, M, Lautar, S, Lee-Wisdom, K, Liang, S, Lin, Q, Lu, MXC, Morgan, L, Thomas, B, Williams, LR, Zhang, J, Zhou, Y & Kalish, VJ 2003, 'Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries', Bioorganic and Medicinal Chemistry, vol. 11, no. 17, pp. 3695-3707. https://doi.org/10.1016/S0968-0896(03)00333-X
Ferraris, Dana ; Ficco, Rica Pargas ; Dain, David ; Ginski, Mark ; Lautar, Susan ; Lee-Wisdom, Kathy ; Liang, Shi ; Lin, Qian ; Lu, May X C ; Morgan, Lisa ; Thomas, Bert ; Williams, Lawrence R. ; Zhang, Jie ; Zhou, Yinong ; Kalish, Vincent J. / Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4 : Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. In: Bioorganic and Medicinal Chemistry. 2003 ; Vol. 11, No. 17. pp. 3695-3707.
@article{02f7ded0dc594623b25ef2ccc3a109a0,
title = "Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries",
abstract = "A class of poly(ADP-ribose) polymerase (PARP-1) inhibitors, the imidazobenzodiazepines, are presented in this text. Several derivatives were designed and synthesized with ionizable groups (i.e., tertiary amines) in order to promote the desired pharmaceutical characteristics for administration in ischemic injury. Within this series, several compounds have excellent in vitro potency and our computational models accurately justify the structure-activity relationships (SARs) and highlight essential hydrogen bonding residues and hydrophobic pockets within the catalytic domain of PARP-1. Administration of these compounds (5q, 17a and 17e) in the mouse model of streptozotocin-induced diabetes results in maintainance of glucose levels. Furthermore, one such inhibitor (5g, IC50=26 nM) demonstrated significant reduction of infarct volume in the rat model of permanent focal cerebral ischemia.",
author = "Dana Ferraris and Ficco, {Rica Pargas} and David Dain and Mark Ginski and Susan Lautar and Kathy Lee-Wisdom and Shi Liang and Qian Lin and Lu, {May X C} and Lisa Morgan and Bert Thomas and Williams, {Lawrence R.} and Jie Zhang and Yinong Zhou and Kalish, {Vincent J.}",
year = "2003",
month = "8",
day = "15",
doi = "10.1016/S0968-0896(03)00333-X",
language = "English (US)",
volume = "11",
pages = "3695--3707",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4

T2 - Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries

AU - Ferraris, Dana

AU - Ficco, Rica Pargas

AU - Dain, David

AU - Ginski, Mark

AU - Lautar, Susan

AU - Lee-Wisdom, Kathy

AU - Liang, Shi

AU - Lin, Qian

AU - Lu, May X C

AU - Morgan, Lisa

AU - Thomas, Bert

AU - Williams, Lawrence R.

AU - Zhang, Jie

AU - Zhou, Yinong

AU - Kalish, Vincent J.

PY - 2003/8/15

Y1 - 2003/8/15

N2 - A class of poly(ADP-ribose) polymerase (PARP-1) inhibitors, the imidazobenzodiazepines, are presented in this text. Several derivatives were designed and synthesized with ionizable groups (i.e., tertiary amines) in order to promote the desired pharmaceutical characteristics for administration in ischemic injury. Within this series, several compounds have excellent in vitro potency and our computational models accurately justify the structure-activity relationships (SARs) and highlight essential hydrogen bonding residues and hydrophobic pockets within the catalytic domain of PARP-1. Administration of these compounds (5q, 17a and 17e) in the mouse model of streptozotocin-induced diabetes results in maintainance of glucose levels. Furthermore, one such inhibitor (5g, IC50=26 nM) demonstrated significant reduction of infarct volume in the rat model of permanent focal cerebral ischemia.

AB - A class of poly(ADP-ribose) polymerase (PARP-1) inhibitors, the imidazobenzodiazepines, are presented in this text. Several derivatives were designed and synthesized with ionizable groups (i.e., tertiary amines) in order to promote the desired pharmaceutical characteristics for administration in ischemic injury. Within this series, several compounds have excellent in vitro potency and our computational models accurately justify the structure-activity relationships (SARs) and highlight essential hydrogen bonding residues and hydrophobic pockets within the catalytic domain of PARP-1. Administration of these compounds (5q, 17a and 17e) in the mouse model of streptozotocin-induced diabetes results in maintainance of glucose levels. Furthermore, one such inhibitor (5g, IC50=26 nM) demonstrated significant reduction of infarct volume in the rat model of permanent focal cerebral ischemia.

UR - http://www.scopus.com/inward/record.url?scp=12444286415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444286415&partnerID=8YFLogxK

U2 - 10.1016/S0968-0896(03)00333-X

DO - 10.1016/S0968-0896(03)00333-X

M3 - Article

C2 - 12901915

AN - SCOPUS:12444286415

VL - 11

SP - 3695

EP - 3707

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 17

ER -